March 2026 was the busiest month in neurotech funding history — $358.7M raised across 5 companies
Summary
March 2026 was the busiest month by disclosed capital in neurotechnology history, with approximately $358.7M raised across Science Corporation ($230M Series C), Cognito Therapeutics ($105M Series C oversubscribed), Gestala ($21.7M angel), Mave Health ($2.1M seed), and Neurolief ($6M milestone-based from BrainsWay). The month demonstrated that late-stage therapeutic neurotechnology companies raise substantially larger rounds than consumer neurotech, with Science Corp and Cognito together accounting for 93% of March capital. This concentration in clinical-stage companies with regulatory progress signals investor maturation toward evidence-based rather than speculative bets.
Why it matters
A single month with $358.7M across 5 deals is unprecedented for neurotech and signals the sector has definitively crossed into mainstream investment territory. The pattern — concentrated in clinical-stage companies with regulatory milestones (PRIMA in NEJM, Spectris approaching pivotal readout) — shows sophisticated investors pricing specific de-risking events rather than backing sector hype.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial